Financial Management Network Inc. Purchases New Position in Novo Nordisk A/S (NYSE:NVO)

Financial Management Network Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,826 shares of the company’s stock, valued at approximately $248,000.

Other institutional investors have also recently made changes to their positions in the company. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Center for Financial Planning Inc. lifted its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the third quarter worth about $42,000. Dunhill Financial LLC lifted its stake in Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after purchasing an additional 311 shares during the last quarter. Finally, Albion Financial Group UT lifted its stake in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $82.44 on Wednesday. The firm has a market cap of $369.97 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. The firm’s 50 day simple moving average is $87.45 and its 200-day simple moving average is $108.84. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.